Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of preheated and repeated preheated versus conventional bulk fill resin composite

Conditions: Dental Leakage

Summary: a randomized clinical trial to evaluate the clinical performance of posterior restorations of bulk fill resin composite without preheating versus repeated preheating for one, five and ten times .the null hypothesis of this study is that there is no significant difference in clinical performance of the restoration during restoring posterior teeth when using bulk-fill without preheating and after repeated preheating for one , five and ten times in restoration of posterior teeth.

dental resin composites are widely used for adhesive restorative procedures nowadays due to the significant improvement in their physical and mechanical properties. however, volumetric shrinkage is still an inherent drawback of the polymerization of the resin matrix . preheating improves adaptation, polymerization shrinkage and degree of conversion without affect mechanical properties of resin composite restorations. in clinical situation, composite resin syringe is repeatedly used for restoration of several cavities and if preheating is applied, this syringe will undergo several heating cycles so repeated preheating effect on composite resin should be tested. follow up period will be 1 year , evaluation will be done at 3,6,9 and 12 months .

Eligibility criteria:
inclusion criteria: * a)inclusion criteria of participants 1. patient age between (18-60) years old. 2. patient is capable of informed consent. 3-patients with a high level of oral hygiene. b)inclusion criteria of teeth: 1. vital teeth 2. carious molar teeth. exclusion criteria: * a)exclusion criteria of participants 1. participants with general systematic illness. 2. experience with allergic reactions against any component of used materials. 3. concomitant participation in another research study. 4. patients receiving orthodontic treatment. 5. pregnant or lactating females. 6. patient with heavy bruxism habits. b)exclusion criteria of the teeth 1. the tooth to be filled is an abutment tooth for a removable prosthesis. 2. the tooth to be filled is periodontally involved (grade 2 or grade 3 mobile). 3. endodontically treated tooth. 4. tooth with previous restoration 5. exposed tooth.
preterm deli̇very and myocine binding protein c levels

Conditions: Preterm

Summary: it was aimed to evaluate if mbpc can be used in prediction of early birth. taking the first trimester from pregnancy was stored until the timing of delivery.the participants were separated into two groups according to the time of birth, early and timely. serum mbpc levels between two groups evaluated.

it was aimed to evaluate if mbpc can be used in prediction of early birth. taking the first trimester from pregnancy was stored until the timing of delivery.the participants were separated into two groups according to the time of birth, early and timely. serum mbpc levels between two groups evaluated.a total of 90 women were planned to include 45 study 45 control group in the study.

Eligibility criteria:
inclusion criteria: * being pregnant in the first trimester * be between 18-40 years old exclusion criteria: * no history of preterm birth * being pregnant with assisted reproductive techniques * having a multiple pregnancy * have cervical insufficiency

Keywords: preterm deli̇very, mbpc,
magnetic resonance spectroscopy in autonomic failure

Conditions: Pure Autonomic Failure; Multiple System Atrophy

Summary: this research study will be conducted in patients with primary autonomic failure, a disabling condition that is associated with low blood pressure upon standing. these patients are also not able to control for changes in their blood pressure due to a loss of cardiovascular reflexes that are mediated within the brain. the purpose of this study is to determine whether magnetic resonance spectroscopy (mrs), a non-invasive imaging technique, can measure levels of chemicals (neurotransmitters) in the dorsal medulla, a brain area important for control of cardiovascular function, in autonomic failure patients. importantly, this study will determine whether there are differences in brain chemicals between patients with peripheral versus central origins of their autonomic failure. the hypothesis is that the neurotransmitter profile in the medulla will be intact in patients with peripheral autonomic failure compared to those with central impairment. overall, this study will provide insight into understanding the mechanisms involved in autonomic failure and will determine whether a single session of mrs imaging can improve the ability to make an accurate diagnosis in these patients. this would lessen the need for more extensive and invasive clinical testing.


Eligibility criteria:
inclusion criteria: * patients with primary autonomic failure who are already participating in the approved vanderbilt study "evaluation and treatment of autonomic failure" * males and females of all races between 18 and 80 years of age * able and willing to provide informed consent exclusion criteria: * pregnant women * patients with diagnosed parkinson's disease or secondary forms of autonomic failure * patients with severe claustrophobia * patients taking medications known to affect brain neurotransmitter levels \[e.g., anti-depressants, barbiturates, benzodiazepines, gabapentin, namenda, sinemet\] * patients with implanted medical devices \[e.g., pacemakers, metal clips, cochlear implants, orthopedic hardware\], lead-based tattoos or pieces of metal close to or in an important organ * high-risk patients \[e.g., heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction\] * inability to give or withdraw informed consent * other factors which in the investigator's opinion would prevent the subject from completing the protocol including significant abnormalities in clinical, mental, or laboratory testing

Keywords: autonomic failure mangenetic resonance neurochemistry neurotransmitter glutamate
the value of infectious biomarkers for prediction of complication after hepatopancreatobiliary surgery

Conditions: Post-operative Complication

Summary: post operative complication after hepatopancreatobiliary surgery is high as 30-50%，which is the main reason for patient admitted to icu. several biomarkers have been shown to be useful in the early diagnosis of sepsis and systemic bacterial infection. the purpose of this study is to assess the predictive value of biomarkers for early complication after hepatopancreatobiliary surgery and assess the effectiveness of anti-infectious therapy.

postoperative complication after major abdominal surgery, such as pancreatic surgery and hilar cholangiocarcinoma surgery, is higher, up to 30 to 50%.it is the mainly reason for the patient to admit to icu. among this, the most common and difficult to handle complication is mainly anastomotic fistula, abdominal effusion and subsequent secondary infection. delayed diagnosis can cause systemic inflammatory response syndrome (sirs), multiple organ failure ( mods), and even death. from a surgical point of view, it leads to surgical failure and often need the second surgery. however, the diagnosis and treatment of postoperative infection is also facing two problems: it is difficult to confirm the diagnosis and make treatment decision. hence, there is a strong need of an additional tool to early diagnose post operative complication. serum procalcitonin (pct), is a 116 amino-acids protein produced by c-cells of the thyroid gland. pct baseline levels are low (\<0.05 ng/ml), but increase significantly in patients with severe bacterial infections. therefore, pct levels are used to monitor the course and prognosis of systemic bacterial infections and to tailor the therapeutic interventions more efficiently. furthermore, pct could serve as an early predictive marker for the clinical course of septic complications after abdominal surgery. the aim of this study is to demonstrate if pct is a more sensible, specific and reliable biomarker of post operative complication than other biomarkers the investigators conducted a observational, prospective study. all patients undergoing electively hepatopancreatobiliary surgery in seven centres are recruited. in all cases white blood count (wbc), c-reactive protein (crp) and pct levels are measured in 1st, 3rd and 5th postoperative day (pod). informed consent was obtained in all patients.the study is approved by the hospital's ethical committee.

Eligibility criteria:
inclusion criteria: * age \> = 18 years * hospitalized patients with elective hepatopancreatobiliary surgery exclusion criteria: * age \<18 years * emergency operative patients * preoperative fever, white blood cell elevation and preoperative infection * systemic inflammatory disease * renal failure * hematology disease * preoperative abnormal pct, il-6, il-8, crp * laparoscopic cholecystectomy * bile duct infection

Keywords: procalcitonin post-operative complication crp
a 6-month study to evaluate sulforaphane effects in schizophrenia patients

Conditions: Schizophrenia

Summary: the goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia. this study will compare the sulforaphane with placebo. there is a thirty percent change (less than half) of receiving the placebo. the purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.

this study will be carried out in the third jiangyin hospital in china and total of 120 schizophrenia patients with one negative symptom item score of panss≥3 will be enrolled into the study. individuals who participate in the study will be followed for 24 weeks. the changes in clinical symptoms and neurocognitive function will be assessed from baseline (week-0) to week-12, and week-24.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic and statistical manual (dsm-5) diagnostic criteria for schizophrenia; 2. first onset or duration of illness less than 30 years with current symptoms in a stable condition; 3. male and female aged 18 to 50 years; 4. total score greater than or equal to 20 on the sum of the seven items constituting the positive and negative syndrome scale (panss) negative symptoms; an item of panss negative symptoms \>3 scores; 5. signed the study consent for participation. exclusion criteria: 1. has a history of substance dependence or abuse or whose symptoms are caused by other diagnosable mental disorders; 2. has a history of traumatic brain injury, seizures, or other known neurological diseases of the central nervous system; 3. taking antidepressants, stimulants, mood stabilizers, or received modified electroconvulsive therapy (mect) or rtms during the past three months; 4. having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be managed during the trial; 5. taking dementia-related drugs, minocycline, and other drugs that may affect cognitive function; 6. laboratory tests indicated significant abnormalities in blood routine, liver and kidney function, or other metabolic results; 7. pregnant or lactating women.

Keywords: schizophrenia sulforaphane
single-center prospective cumulus cell test study in rfsh patients

Conditions: Infertility

Summary: performing an additional non-invasive oocyte diagnostic test based on cumulus cell gene expression could improve the outcome of the art cycle for rfsh stimulated patients


Eligibility criteria:
inclusion criteria: * scheduled for intracytoplasmatic sperm injection (icsi) and single (or double) embryo transfer on day 3 * patients down regulated with gonadotropin-releasing hormone (gnrh) antagonist and stimulated with recombinant follicle stimulating hormone (fsh) * undergoing first or second ivf or icsi cycle with transfer * body mass index (bmi) between 17 and 33 * regular menstrual cycle (between 24 and 35 days) exclusion criteria: * smokers (\> 10 cigarettes per day) * patients requesting pre-implantation genetic diagnosis (pgd) * patients with polycystic ovary syndrome (pcos), or severe endometriosis (afs stage 3-4) * couples where the partner has an extremely low sperm count i.e.: extreme oligo-astheno-teratozoospermia (oat) (\< 100.000/ml) or scheduled for testicular sperm extraction (tese) * results of eventual preceding cycles may not indicate a known genetic disease, or low ovarian response or an oocyte maturation defect
live after an epithelial ovarian cancer: multidisciplinary assessment of effects and long-term remission in patients needs.

Conditions: Epithelial Ovarian Cancer

Summary: this project is part of a large multicenter multidisciplinary program that will thoroughly explore the needs and difficulties of patients with bcr as well as those involved in their care. the results of this research program will propose recommendations for better structure and understand the follow up of these patients. from the limited data in the literature, the long-term remission in patients with ovarian cancer reported a significant and persistent fatigue, poor qol, disorders of sexuality as well as somatic and mental illness; consumption is also a medical records for these patients. in this context, our team has initiated a large case-control study to assess fatigue (identified major problem in the long-term remission in patients with ovarian cancer), qol and rehabilitation of patients in remission from an epithelial ovarian cancer (regardless of the stage of cancer at diagnosis, early or advanced) 3 years after the initial treatment, compared with women of the same age without ovarian cancer or serious chronic disease , from the general population. patients and controls complement standardized and validated self-administered questionnaire (part 1). this study investigated 215 patients in long remission from ovarian cancer compared to 215 women of the same age without cancer. recruitment of patients is currently underway, in close collaboration with teams from the group gineco very involved in this project. following this step, an additional component is planned: it is to offer patients who participated in part 1, a specific gynecological consultation to assess in detail the effects of the treatments in order to better meet the needs of patients .dropoff window


Eligibility criteria:
inclusion criteria: * age\> 18 years; * patients who received optimal treatment (surgery, chemotherapy ...) * patients with epithelial ovarian cancer after first-line treatment; * patients without other cancer (except basal cell skin carcinoma and breast cancer in situ); * patients without clinical relapse, biological or radiological documented at least 3 years after the initial treatment (from the end date of first line chemotherapy); * the interviews treatments are not recognized in the period; * patients may be included regardless of the stage of cancer at diagnosis (early or late) * patients who have signed their written consent to participate in the part 2 of the study vivrovaire; * patients who participated in part 1 of vivrovaire study. exclusion criteria: * psychiatric pathology can disrupt the conduct of the study or to prevent the interpretation of results; * persons deprived of liberty; * major subject to a measure of legal protection or unable to consent.

Keywords: ovarian cancer quality of life remission more than 3 years
delivering group support for people with aphasia through eva park

Conditions: Aphasia

Summary: the project will investigate the feasibility and acceptability of a remote support group intervention for people with aphasia, and will investigate the impact of that intervention on measures of wellbeing, quality of life and communication. the intervention will be delivered to 32 participants in eva park, a virtual island specifically designed for people with aphasia.


Eligibility criteria:
inclusion criteria: * stroke survivor with aphasia; score within the aphasic range on the frenchay aphasia screening test (fast); fluent pre-stroke user of english. exclusion criteria: * co-morbidity affecting cognition; severe hearing or visual impairments

Keywords: social support
efficacy and safety of acetaminophen, aspirin and caffeine with sumatriptan in the acute treatment of migraine

Conditions: Pain, Migraine

Summary: the main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (aac) with sumatriptan and placebo in the acute treatment of migraine.


Eligibility criteria:
inclusion criteria: 1. male or female aged 18 years and over. 2. international headache society (ihs) diagnosis of migraine without aura or typical aura with migraine headache. 3. history of experiencing at least 1, but not more than 8, acute migraine attacks monthly during the previous year. 4. history of at least moderate migraine pain intensity, if left untreated. exclusion criteria: 1. headache symptoms which may be due to or aggravated by: * recent (within 6 months) head or neck trauma (e.g., whiplash) * head or neck pain secondary to an orthopedic abnormality * cluster headache * specific migraine variants (e.g., basilar-type artery migraine, ophthalmoplegic migraine, hemiplegic migraine, migraine aura without headache) * other serious, non-migraine causes of headache (e.g., increased intracranial pressure, intracranial bleeding, meningitis, malignancy) * non-serious, non-migraine causes of headache (e.g., cold, flu, hangover) 2. routine use (≥ 10 days per month, on average) of any medication having the potential to interfere with the pharmacologic effects or evaluation of the study medications (e.g., narcotic and non-narcotic analgesic products (prescription or over-the-counter), ergotamine-containing and ergot-type medication, anxiolytics, hypnotics, sedatives, 5ht-1 agonists, anti-emetics, or prokinetic drugs). 3. history of vomiting during more than 20% of migraine episodes or confined to bedrest for more than 50% of migraine episodes. other protocol-defined inclusion/exclusion criteria may apply

Keywords: pain, migraine
vortioxetine add-on treatment improves the symptoms in patients with bipolar depression

Conditions: Bipolar Disorder Depression

Summary: the purpose of this study is to validate the efficacy of vortioxetine augmentation in bipolar disorder patients with depressive symptoms.

in this study, the investigators are going to examine the efficacy of vortioxetine augmentation in bipolar disorder patients with depressive symptoms. the study design is a double-blinded 6-week prospective study. it would be useful for clinicians because it will provide new evidence for the effect of vortioxetine in bipolar disorder patients with depressive symptoms.

Eligibility criteria:
inclusion criteria: * patients diagnosed with bipolar i disorder, bipolar ii disorder, other specified bipolar and related disorder, unspecified bipolar and related disorder by diagnostic and statistical manual (dsm)-v criteria. * 18 to 65 years of age * patients with montgomery-åsberg depression rating scale score ≥ 23 (moderate to severe depression), after 4 weeks or more of treatment by main medication of mood stabilizer or antipsychotics * patients with young mania rating scale score lower than 10, after 4 weeks or more of treatment by main medication of mood stabilizer or antipsychotics exclusion criteria: * currently experiencing manic, hypomanic, or mixed episode * comorbid with serious medical illness * comorbid with substance use disorder, medical illness or other neurologic disorder that may have caused depressive symptoms other than by bipolar disorder * pregnancy or breastfeeding women * those who are hypersensitive to the main or other ingredient of the medication * currently on monoamine oxidase (mao) inhibitor or those who have discontinued mao inhibitor in the last 14 days * severe liver disease, severe renal disease * bleeding tendency/disorder

Keywords: bipolar disorder depression, bipolar vortioxetine
extended wear of a steel and a teflon insulin infusion set

Conditions: Diabetes Mellitus, Type 1

Summary: this is a cross-over study to evaluate if insulin infusion sets can be used up to 7 days.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 1 diabetes for at least 12 months * using an insulin pump for at least 12 months * age ≥18 years * hemoglobin a1c level less than or equal to 8.5% * willing to use mylife™ ypsopump® system while they are participating in the study * willing to use novorapid® insulin while they are participating in the study * an understanding of and willingness to follow the protocol and sign the informed consent exclusion criteria: * diabetic ketoacidosis in the past 3 months prior to enrollment * severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment * urea, creatinine, alt more than three times the upper limit of normal, or thrombocytopenia (\<150 g/l) * female subjects: pregnancy, lactation period, lack of a negative pregnancy test (except in case of menopause, sterilization or hysterectomy), or unwilling to use an acceptable form of contraception during the study (for sexually active subjects of childbearing potential) * known severe tape reactions or allergies * known severe nickel allergies * history of frequent catheter abscesses associated with pump therapy * serious acute or chronic disease besides diabetes mellitus or an anamnesis which might, in the opinion of the investigator, pose a risk to the subject, e.g. seizure disorder, adrenal disorder, dialysis for renal failure, cystic fibrosis, active infection * any incapacity or general condition that, in the opinion of the investigator, prevents adequate compliance with the study procedures, e.g. mental or visual incapacity, language barriers, alcohol or drug misuse * dependency from the sponsor or the clinical investigator
effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure

Conditions: Congestive Heart Failure; Type II Diabetes Mellitus

Summary: this study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (nyha class i-iii). effect on hba1c and overall safety and tolerability will also be assessed.


Eligibility criteria:
inclusion criteria: * patients with t2dm, diagnosed at least 3 months prior to visit 1 * chf (nyha class i, class ii, or class iii) at visit 1 * lvef \< 40% exclusion criteria: * pregnant or lactating female * fpg ≥ 270 mg/dl (≥15 mmol/l)

Keywords: congestive heart failure chf, vildagliptin metabolic disease cardiovascular disease t2dm